Development of abuse-deterrent nanotechnology formulation for effective pain management

Altus制剂公司专注于药物输送技术的开发，以产生具有成本效益的“安全使用”产品，以改善患者的生活。Altus开发了一系列创新的两亲性和ph敏感性嵌段共聚物，这些嵌段共聚物可以在水介质中自组装，形成纳米级嵌段共聚物胶束（bcm），将药物捕获在其核心内并实现药物输送。这种专有的嵌段共聚物系列包括形成胶束外壳的聚乙二醇（PEG）亲水嵌段和由聚甲基丙烯酸酯和聚甲基丙烯酸丁酯（简称：PMA）的随机共聚物组成的成核药物捕获嵌段。PMA核形成块的性质是它将药物保持在非结晶形式，并在通过胃的运输过程中保护药物；由于其对pH值的敏感性，PMA阻断剂允许药物在小肠中进行特定部位的释放，因为小肠是药物吸收最大化的地方。为此，Altus已经进行了临床前研究，证明PEG-b-PMA共聚物胶束在口服给药后有效递送疏水抗癌药物的能力。Altus现在有兴趣扩大这一系列有前途的材料的使用，以创建专有配方的活性剂作为口服控释液体，有效地管理疼痛。

Altus Formulation Inc. is focused on the development of drug delivery technologies to generate cost effective 'safe to use' products to improve the lives of patients. Altus has developed an innovative series of amphiphilic and pH-sensitive block copolymers that can self-assemble in aqueous media to form nano-sized block copolymer micelles (BCMs) that entrap drugs within their cores and enable drug delivery. This proprietary series of block copolymers includes a poly(ethylene glycol) (PEG) hydrophilic block that forms the outer shell of the micelles and a core-forming, drug trapping block that is comprised of a random copolymer of polymethacrylate and poly(t-butyl methacrylate) (abbreviated: PMA). The nature of the PMA core-forming block is such that it retains the drug in a non-crystalline form and protects it during transit through the stomach; due to its pH sensitivity the PMA block allows site-specific release of the drug once in the small intestine where drug absorption is maximized. To this point, Altus has conducted pre-clinical studies demonstrating the ability of PEG-b-PMA copolymer micelles to effectively deliver hydrophobic anti-cancer drugs following oral administration. Altus is now interested in expanding the use of this promising series of materials to create proprietary formulations of active agents as oral controlled release liquids for effective pain management.